Recent Updates
Recently added Catalysts
HRMY Positive Sentiment

Harmony Biosciences to Participate in Upcoming Investor Conferences

Key Takeaway: Harmony Biosciences announced its participation in upcoming investor conferences, including the Evercore Healthcare Conference and the Piper Sandler Healthcare Conference. The management team will engage in fireside chats and one-on-one meetings with investors. The company continues to develop innovative medicines for CNS disorders, building on its success with WAKIX.
Price reaction · baseline $33.11 (2026-11-18 close) · hit pre-market · clean, no other HRMY news in the window
day 0 close · peak
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Management team will participate in multiple investor conferences.
  • Webcasts of fireside chats will be available for investors.
  • Company is advancing a novel clinical-stage pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
7.9%
average across 7 past catalysts
Lead asset
HBS-301
Phase 3 · Idiopathic Hypersomnia

Full Press Release Details

PLYMOUTH MEETING, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in the following upcoming investor conferences.

9th Annual Evercore Healthcare Conference

• Location: Miami, FL
• Fireside Chat: November 30, 2026, at 4:15 p.m. ET
• One-on-One Investor Meetings: December 1, 2026

Piper Sandler 38th Annual Healthcare Conference

• Location: New York, NY
• Fireside Chat: December 3, 2026, at 11:00 a.m. ET
Webcasts of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders. For more information, visit: www.harmonybiosciences.com.

Harmony Biosciences Investor Contact: Brennan Doyle 484-566-3685 bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact: Cate McCanless 202-641-6086 cmccanless@harmonybiosciences.com

Frequently Asked Questions

What conferences will Harmony Biosciences attend?

Harmony Biosciences will attend the Evercore and Piper Sandler conferences.

When is the fireside chat at the Evercore Conference?

The fireside chat is scheduled for November 30, 2026, at 4:15 p.m. ET.

What is WAKIX?

WAKIX is the first FDA-approved treatment for excessive daytime sleepiness in narcolepsy.

Where can I watch the webcasts of the conferences?

Webcasts will be available on the Harmony Biosciences investor page.

Last updated: Nov 19, 2026